Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Singh S, Gleason CE, Fang M, Laimon YN, Khivansara V, Xie S, Durmaz YT, Sarkar A, Ngo K, Savla V, Li Y, Abu-Remaileh M, Li X, Locquet MA, Tuladhar B, Odeh R, Hamkins-Indik F, He D, Membreno MW, Nosrati M, Gushwa NN, Leung SSF, Fraga-Walton B, Hernandez L, Baldomero MP, Lent BM, Spellmeyer D, Luna JF, Hoang D, Gritsenko Y, Chand M, DeMart MK, Metobo S, Bhatt C, Shapiro JA, Yang K, Dupper NJ, Bockus AT, Fang J, Bambal R, Cremin P, Doench JG, Aggen JB, Liu LF, Levin B, Wang EW, Vendrell I, Fischer R, Kessler B, Gokhale PC, Signoretti S, Spektor A, Kreatsoulas C, Evangelista M, Singh R, Earp DJ, Nijhawan D, Garcia PD, Oser MG.
Singh S, et al. Among authors: vendrell i.
Nature. 2025 Aug 20. doi: 10.1038/s41586-025-09433-w. Online ahead of print.
Nature. 2025.
PMID: 40836083